MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
Portfolio Pulse from Lara Goldstein
Numinus Wellness (OTC:NUMIF) will utilize Optimi Health’s (OTC:OPTHF) GMP-compliant MDMA for a therapist-experiential training program in Canada, supported by MAPS. PharmAla Biotech Holdings (OTC:PMBHF) has received a permit to export its GMP-compliant MDMA LaNeo to the University of Sydney.
June 20, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Numinus Wellness partners with Optimi Health for a therapist-experiential training program using GMP-compliant MDMA.
The partnership with Optimi Health will provide Numinus Wellness with GMP-compliant MDMA for their therapist-experiential training program, which could lead to increased adoption of their psychedelic-assisted therapy services. This is likely to have a positive impact on their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Optimi Health's GMP-compliant MDMA will be used in Numinus Wellness' therapist-experiential training program.
Optimi Health's GMP-compliant MDMA being used in Numinus Wellness' therapist-experiential training program showcases the quality of their product and could lead to increased demand for their MDMA. This is likely to have a positive impact on their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
PharmAla Biotech has received a permit to export its GMP-compliant MDMA LaNeo to the University of Sydney.
PharmAla Biotech's permit to export its GMP-compliant MDMA LaNeo to the University of Sydney demonstrates the company's ability to expand its market reach and fulfill contracts. This is likely to have a positive impact on their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100